Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Oncoswitch

Financiado

Cerrado

In vivo analysis of the p53 and p73 tumor suppressors using a unique mouse model

Cancer is the second cause of death in Europe, after cardiovascular diseases. These lethal diseases are in desperate need of new therapeutic approaches: despite dramatic advances in the use of conventional chemo and radiotherapy a... ver más

31/08/2015

THE CHANCELLOR MAS...

209K€

Presupuesto del proyecto: 209K€

Líder del proyecto

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2015-08-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

THE CHANCELLOR MASTERS AND S...

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2009-12295 ESTRATEGIA ANTITUMORAL COMBINADA: AGENTES FARMACOLOGICOS Y G... 97K€ Cerrado

Cancer-Drug-Screen High throughput drug screening for identifying personalized... 150K€ Cerrado

SAF2010-19710 AURORA A: FUNCIONES ESENCIALES IN VIVO, VALIDACION COMO DIAN... 157K€ Cerrado

SAF2014-60507-JIN IDENTIFICACION DE DETERMINANTES MOLECULARES Y NUEVAS DIANAS... 206K€ Cerrado

TRANSREAD Restoration of tumor suppressor function by induction of tra... 2M€ Cerrado

BCSC-ST Breast cancer stem like cells specific vulnerabilities focu... 195K€ Cerrado

Líder del proyecto

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 209K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cancer is the second cause of death in Europe, after cardiovascular diseases. These lethal diseases are in desperate need of new therapeutic approaches: despite dramatic advances in the use of conventional chemo and radiotherapy and the growth of more targeted drugs, many cancers are still incurable. Cancers are difficult to treat not because they are so mechanistically diverse (indeed, we argue that cancers are not very diverse mechanistically) but because they evolve in response to any pharmacological elective pressure we impose upon them. To address this problem, we employ a novel class of genetically engineered mouse (GEM) in which individual tumour suppressor genes may be systemically toggled off and on, reversibly and at will, in vivo. In this way we can identify the most effective therapeutic targets. We hypothesize that targeting the functionally non-degenerate signaling nodes that link robust networks offers two unique advantages as a therapeutic strategy: a durable therapeutic response, and the possibility for treating many distinct cancer types. In this project, we will focus our attention to the non-redundant tumor suppressor p53, and investigate its relevance as a discrete or combined therapeutic target for the treatment of cancer and protection of individuals from radiological or chemotherapeutic injury. Furthermore we will also examine the potential tumour suppressor role of p73, with the same technical approach. Our overarching aim is to deliver to the pharmaceutical industry pre-clinical models of what drugs would do, both therapeutically and in terms of side effects, were we are able to target any intracellular effector of choice.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores